Top section
Top section
Both tranches price at the investor-friendly end as cloud company raises to fund expansion
Never mind that your desk had a great year, writes Craig. When it comes to getting paid, the future makes a stronger argument than the past
Top 25 shareholders and new investors participate in previously delayed offering, but some shares left over after subscriptions closed
More articles
More articles
More articles
-
Chinese firm Ascletis Pharma has launched bookbuilding for a HK$3.58bn ($456.9m) IPO, the first company to take advantage of the Hong Kong Stock Exchange’s new biotechnology-friendly listing regime. -
The Hong Kong Stock Exchange and China’s two largest bourses have reached a consensus on when dual-class share companies can be included on the Stock Connect, following a surprise decision by the latter to exclude weighted voting rights (WVR) shares from the southbound channel of the cross-border trading system.
-
CanSino Biologics, founded by a group of Chinese vaccination industry experts from Canada, has filed for a listing in Hong Kong.
-
The UK government’s white paper on Brexit, presented as a way of moving negotiations forward with the EU, disappointed many in the UK financial services industry. However, the increasing likelihood of no Brexit deal at all means that disappointment doesn't matter — the proposals laid out in the white paper are little more than noise.
-
Goldman Sachs announced on Tuesday that chief executive and chairman Lloyd Blankfein will retire, and David Solomon will replace him in both roles.
-
Equity investor sentiment remains fragile as buyers become more bearish on global markets because of heightened economic tensions between the US and China. Some investors see this as the most potent risk to equity markets since the eurozone debt crisis.
Sub-sections
shared comment list
